Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field

•Analysis of biological and clinical implications of rare or non-canonical variants in potentially druggable drivers (e.g. EGFR) is challenging and requires extensive resources.•Sequencing data of > 4000 NSCLC were comprehensively analyzed for non-canonical variants.•5.5 % non-canonical mutations are potentially druggable.•Comprehensive up-to-date resource for molecular tumorboards and clinical decision making.